

13100013D

HOUSE BILL NO. 1422

Offered January 9, 2013

Prefiled December 19, 2012

A *BILL to amend and reenact §§ 54.1-3401 and 54.1-3457 of the Code of Virginia and to amend the Code of Virginia by adding a section numbered 54.1-3408.04, relating to dispensing of interchangeable biosimilar biological products.*

Patrons—O'Bannon, Bell, Richard P., Cox, M.K., Dance, Hodges, Howell, W.J., Jones, Orrock, Peace, Ransone, Sickles and Yost; Senators: Barker, Hanger, Howell, Martin, Reeves, Saslaw and Vogel

Referred to Committee on Health, Welfare and Institutions

Be it enacted by the General Assembly of Virginia:

1. That §§ 54.1-3401 and 54.1-3457 of the Code of Virginia are amended and reenacted and that the Code of Virginia is amended by adding a section numbered 54.1-3408.04 as follows:

§ 54.1-3401. Definitions.

As used in this chapter, unless the context requires a different meaning:

"Administer" means the direct application of a controlled substance, whether by injection, inhalation, ingestion, or any other means, to the body of a patient or research subject by (i) a practitioner or by his authorized agent and under his direction or (ii) the patient or research subject at the direction and in the presence of the practitioner.

"Advertisement" means all representations disseminated in any manner or by any means, other than by labeling, for the purpose of inducing, or which are likely to induce, directly or indirectly, the purchase of drugs or devices.

"Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser. It does not include a common or contract carrier, public warehouseman, or employee of the carrier or warehouseman.

"Anabolic steroid" means any drug or hormonal substance, chemically and pharmacologically related to testosterone, other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone.

"Animal" means any nonhuman animate being endowed with the power of voluntary action.

"Automated drug dispensing system" means a mechanical or electronic system that performs operations or activities, other than compounding or administration, relating to pharmacy services, including the storage, dispensing, or distribution of drugs and the collection, control, and maintenance of all transaction information, to provide security and accountability for such drugs.

"Biological product" means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

"Biosimilar" means a biological product that is highly similar to a specific reference biological product, notwithstanding minor differences in clinically inactive compounds, such that there are no clinically meaningful differences between the reference biological product and the biological product that has been licensed as a biosimilar pursuant to 42 U.S.C. § 262(k) in terms of safety, purity, and potency of the product.

"Board" means the Board of Pharmacy.

"Bulk drug substance" means any substance that is represented for use, and that, when used in the compounding, manufacturing, processing, or packaging of a drug, becomes an active ingredient or a finished dosage form of the drug; however, "bulk drug substance" shall not include intermediates that are used in the synthesis of such substances.

"Change of ownership" of an existing entity permitted, registered, or licensed by the Board means (i) the sale or transfer of all or substantially all of the assets of the entity or of any corporation that owns or controls the entity; (ii) the creation of a partnership by a sole proprietor, the dissolution of a partnership, or change in partnership composition; (iii) the acquisition or disposal of 50 percent or more of the outstanding shares of voting stock of a corporation owning the entity or of the parent corporation of a wholly owned subsidiary owning the entity, except that this shall not apply to any corporation the voting stock of which is actively traded on any securities exchange or in any over-the-counter market; (iv) the merger of a corporation owning the entity or of the parent corporation of a wholly-owned subsidiary owning the entity with another business or corporation; or (v) the expiration or forfeiture of a corporation's charter.

INTRODUCED

HB1422

58 "Compounding" means the combining of two or more ingredients to fabricate such ingredients into a
59 single preparation and includes the mixing, assembling, packaging, or labeling of a drug or device (i) by
60 a pharmacist, or within a permitted pharmacy, pursuant to a valid prescription issued for a medicinal or
61 therapeutic purpose in the context of a bona fide practitioner-patient-pharmacist relationship, or in
62 expectation of receiving a valid prescription based on observed prescribing patterns; (ii) by or for a
63 practitioner of medicine, osteopathy, podiatry, dentistry, or veterinary medicine as an incident to his
64 administering or dispensing, if authorized to dispense, a controlled substance in the course of his
65 professional practice; or (iii) for the purpose of, or as incident to, research, teaching, or chemical
66 analysis and not for sale or for dispensing. The mixing, diluting, or reconstituting of a manufacturer's
67 product drugs for the purpose of administration to a patient, when performed by a practitioner of
68 medicine or osteopathy licensed under Chapter 29 (§ 54.1-2900 et seq.) or a person supervised by such
69 practitioner pursuant to ~~subdivisions~~ *subdivision A* 4, 6, or 19 ~~of subsection A~~ of § 54.1-2901, shall not
70 be considered compounding.

71 "Controlled substance" means a drug, substance, or immediate precursor in Schedules I through VI of
72 this chapter. The term shall not include distilled spirits, wine, malt beverages, or tobacco as those terms
73 are defined or used in Title 3.2 or Title 4.1.

74 "DEA" means the Drug Enforcement Administration, ~~United States~~ *U.S.* Department of Justice, or its
75 successor agency.

76 "Deliver" or "delivery" means the actual, constructive, or attempted transfer of any item regulated by
77 this chapter, whether or not there exists an agency relationship.

78 "Device" means instruments, apparatus, and contrivances, including their components, parts, and
79 accessories, intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in
80 man or animals or to affect the structure or any function of the body of man or animals.

81 "Dialysis care technician" or "dialysis patient care technician" means an individual who is certified
82 by an organization approved by the Board of Health Professions pursuant to Chapter 27.01 (§
83 54.1-2729.1 et seq.) and who, under the supervision of a licensed physician, nurse practitioner, physician
84 assistant, or a registered nurse, assists in the care of patients undergoing renal dialysis treatments in a
85 Medicare-certified renal dialysis facility.

86 "Dialysis solution" means either the commercially available, unopened, sterile solutions whose
87 purpose is to be instilled into the peritoneal cavity during the medical procedure known as peritoneal
88 dialysis, or commercially available solutions whose purpose is to be used in the performance of
89 hemodialysis not to include any solutions administered to the patient intravenously.

90 "Dispense" means to deliver a drug to an ultimate user or research subject by or pursuant to the
91 lawful order of a practitioner, including the prescribing and administering, packaging, labeling, or
92 compounding necessary to prepare the substance for that delivery. However, dispensing shall not include
93 the transportation of drugs mixed, diluted, or reconstituted in accordance with this chapter to other sites
94 operated by such practitioner or that practitioner's medical practice for the purpose of administration of
95 such drugs to patients of the practitioner or that practitioner's medical practice at such other sites. For
96 practitioners of medicine or osteopathy, "dispense" shall only include the provision of drugs by a
97 practitioner to patients to take with them away from the practitioner's place of practice.

98 "Dispenser" means a practitioner who dispenses.

99 "Distribute" means to deliver other than by administering or dispensing a controlled substance.

100 "Distributor" means a person who distributes.

101 "Drug" means (i) articles or substances recognized in the official United States Pharmacopoeia
102 National Formulary or official Homeopathic Pharmacopoeia of the United States, or any supplement to
103 any of them; (ii) articles or substances intended for use in the diagnosis, cure, mitigation, treatment, or
104 prevention of disease in man or animals; (iii) articles or substances, other than food, intended to affect
105 the structure or any function of the body of man or animals; ~~or~~ (iv) articles or substances intended for
106 use as a component of any article specified in clause (i), (ii), or (iii); *or (v) a biological product.* "Drug"
107 does not include devices or their components, parts, or accessories.

108 "Drug product" means a specific drug in dosage form from a known source of manufacture, whether
109 by brand or therapeutically equivalent drug product name.

110 "Electronic transmission prescription" means any prescription, other than an oral or written
111 prescription or a prescription transmitted by facsimile machine, that is electronically transmitted directly
112 to a pharmacy without interception or intervention from a third party from a practitioner authorized to
113 prescribe or from one pharmacy to another pharmacy.

114 "Facsimile (FAX) prescription" means a written prescription or order, ~~which~~ *that* is transmitted by an
115 electronic device over telephone lines that sends the exact image to the receiving pharmacy in hard copy
116 form.

117 "FDA" means the ~~United States~~ *U.S.* Food and Drug Administration.

118 "Hashish oil" means any oily extract containing one or more cannabinoids, but shall not include any
119 such extract with a tetrahydrocannabinol content of less than 12 percent by weight.

120 "Immediate precursor" means a substance which the Board of Pharmacy has found to be and by
 121 regulation designates as being the principal compound commonly used or produced primarily for use,
 122 and which is an immediate chemical intermediary used or likely to be used in the manufacture of a
 123 controlled substance, the control of which is necessary to prevent, curtail, or limit manufacture.

124 "*Interchangeable*" means a biosimilar that meets safety standards for determining interchangeability
 125 pursuant to 42 U.S.C. § 262(k)(4).

126 "Label" means a display of written, printed, or graphic matter upon the immediate container of any
 127 article. A requirement made by or under authority of this chapter that any word, statement, or other
 128 information appear on the label shall not be considered to be complied with unless such word,
 129 statement, or other information also appears on the outside container or wrapper, if any, of the retail
 130 package of such article; or is easily legible through the outside container or wrapper.

131 "Labeling" means all labels and other written, printed, or graphic matter on an article or any of its
 132 containers or wrappers, or accompanying such article.

133 "Manufacture" means the production, preparation, propagation, conversion, or processing of any item
 134 regulated by this chapter, either directly or indirectly by extraction from substances of natural origin, or
 135 independently by means of chemical synthesis, or by a combination of extraction and chemical
 136 synthesis, and includes any packaging or repackaging of the substance or labeling or relabeling of its
 137 container. This term does not include compounding.

138 "Manufacturer" means every person who manufactures.

139 "Marijuana" means any part of a plant of the genus *Cannabis* whether growing or not, its seeds, or
 140 its resin; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its
 141 seeds, or its resin. Marijuana shall not include any oily extract containing one or more cannabinoids
 142 unless such extract contains less than 12 percent of tetrahydrocannabinol by weight, nor shall marijuana
 143 include the mature stalks of such plant, fiber produced from such stalk, or oil or cake made from the
 144 seeds of such plant, unless such stalks, fiber, oil, or cake is combined with other parts of plants of the
 145 genus *Cannabis*.

146 "Medical equipment supplier" means any person, as defined in § 1-230, engaged in the delivery to
 147 the ultimate consumer, pursuant to the lawful order of a practitioner, of hypodermic syringes and
 148 needles, medicinal oxygen, Schedule VI controlled devices, those Schedule VI controlled substances with
 149 no medicinal properties which that are used for the operation and cleaning of medical equipment and
 150 solutions for peritoneal dialysis.

151 "Narcotic drug" means any of the following, whether produced directly or indirectly by extraction
 152 from substances of vegetable origin, or independently by means of chemical synthesis, or by a
 153 combination of extraction and chemical synthesis: (i) opium, opiates, and any salt, compound, derivative,
 154 or preparation of opium or opiates; (ii) any salt, compound, isomer, derivative, or preparation thereof
 155 which is chemically equivalent or identical with any of the substances referred to in clause (i), but not
 156 including the isoquinoline alkaloids of opium; (iii) opium poppy and poppy straw; (iv) coca leaves and
 157 any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, isomer,
 158 derivative, or preparation thereof which is chemically equivalent or identical with any of these
 159 substances, but not including decocainized coca leaves or extraction of coca leaves which do not contain
 160 cocaine or ecgonine.

161 "New drug" means: (i) any drug, except a new animal drug or an animal feed bearing or containing
 162 a new animal drug, the composition of which is such that such drug is not generally recognized, among
 163 experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs,
 164 as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling,
 165 except that such a drug not so recognized shall not be deemed to be a "new drug" if at any time prior
 166 to the enactment of this chapter it was subject to the Food and Drugs Act of June 30, 1906, as
 167 amended, and if at such time its labeling contained the same representations concerning the conditions
 168 of its use; or (ii) any drug, except a new animal drug or an animal feed bearing or containing a new
 169 animal drug, the composition of which is such that such drug, as a result of investigations to determine
 170 its safety and effectiveness for use under such conditions, has become so recognized, but which has not,
 171 otherwise than in such investigations, been used to a material extent or for a material time under such
 172 conditions.

173 "Nuclear medicine technologist" means an individual who holds a current certification with the
 174 American Registry of Radiological Technologists or the Nuclear Medicine Technology Certification
 175 Board.

176 "Official compendium" means the official United States Pharmacopoeia National Formulary, official
 177 Homeopathic Pharmacopoeia of the United States, or any supplement to any of them.

178 "Official written order" means an order written on a form provided for that purpose by the United
 179 States U.S. Drug Enforcement Administration, under any laws of the United States making provision
 180 therefor, if such order forms are authorized and required by federal law, and if no such order form is

181 provided then on an official form provided for that purpose by the Board of Pharmacy.

182 "Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to
183 morphine or being capable of conversion into a drug having such addiction-forming or
184 addiction-sustaining liability. It does not include, unless specifically designated as controlled under
185 Article 4 (§ 54.1-3437 et seq.) ~~of this chapter~~, the dextrorotatory isomer of
186 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). It does include its racemic and
187 levorotatory forms.

188 "Opium poppy" means the plant of the species *Papaver somniferum* L., except the seeds thereof.

189 "Original package" means the unbroken container or wrapping in which any drug or medicine is
190 enclosed together with label and labeling, put up by or for the manufacturer, wholesaler, or distributor
191 for use in the delivery or display of such article.

192 "Person" means both the plural and singular, as the case demands, and includes an individual,
193 partnership, corporation, association, governmental agency, trust, or other institution or entity.

194 "Pharmacist-in-charge" means the person who, being licensed as a pharmacist, signs the application
195 for a pharmacy permit and assumes full legal responsibility for the operation of the relevant pharmacy in
196 a manner complying with the laws and regulations for the practice of pharmacy and the sale and
197 dispensing of controlled substances; the "pharmacist-in-charge" shall personally supervise the pharmacy
198 and the pharmacy's personnel as required by § 54.1-3432.

199 "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.

200 "Practitioner" means a physician, dentist, licensed nurse practitioner pursuant to § 54.1-2957.01,
201 licensed physician assistant pursuant to § 54.1-2952.1, pharmacist pursuant to § 54.1-3300, TPA-certified
202 optometrist pursuant to Article 5 (§ 54.1-3222 et seq.) of Chapter 32, veterinarian, scientific investigator,
203 or other person licensed, registered, or otherwise permitted to distribute, dispense, prescribe and
204 administer, or conduct research with respect to; a controlled substance in the course of professional
205 practice or research in the Commonwealth.

206 "Prescriber" means a practitioner who is authorized pursuant to §§ 54.1-3303 and 54.1-3408 to issue
207 a prescription.

208 "Prescription" means an order for drugs or medical supplies, written or signed or transmitted by word
209 of mouth, telephone, telegraph, or other means of communication to a pharmacist by a duly licensed
210 physician, dentist, veterinarian, or other practitioner; authorized by law to prescribe and administer such
211 drugs or medical supplies.

212 "Prescription drug" means any drug required by federal law or regulation to be dispensed only
213 pursuant to a prescription, including finished dosage forms and active ingredients subject to § 503 (b) of
214 the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 353 (b)).

215 "Production" or "produce" includes the manufacture, planting, cultivation, growing, or harvesting of a
216 controlled substance or marijuana.

217 "Proprietary medicine" means a completely compounded nonprescription drug in its unbroken,
218 original package which does not contain any controlled substance or marijuana as defined in this chapter
219 and is not in itself poisonous, and which is sold, offered, promoted, or advertised directly to the general
220 public by or under the authority of the manufacturer or primary distributor, under a trademark, trade
221 name, or other trade symbol privately owned, and the labeling of which conforms to the requirements of
222 this chapter and applicable federal law. However, this definition shall not include a drug ~~which that~~ is
223 only advertised or promoted professionally to licensed practitioners, a narcotic or drug containing a
224 narcotic, a drug ~~which that~~ may be dispensed only upon prescription or the label of which bears
225 substantially the statement "Warning - may be habit-forming," or a drug intended for injection.

226 "Radiopharmaceutical" means any drug that exhibits spontaneous disintegration of unstable nuclei
227 with the emission of nuclear particles or photons and includes any non-radioactive reagent kit or
228 radionuclide generator that is intended to be used in the preparation of any such substance, but does not
229 include drugs such as carbon-containing compounds or potassium-containing salts that include trace
230 quantities of naturally occurring radionuclides. The term also includes any biological product that is
231 labeled with a radionuclide or intended solely to be labeled with a radionuclide.

232 "*Reference biological product*" means the single biological product licensed pursuant to 42 U.S.C.
233 § 262(a) against which a biological product is evaluated in an application submitted to the U.S. Food
234 and Drug Administration for licensure of biological products as biosimilar or interchangeable pursuant
235 to 42 U.S.C. § 262(k).

236 "Sale" includes barter, exchange, or gift, or offer therefor, and each such transaction made by any
237 person, whether as an individual, proprietor, agent, servant, or employee.

238 "Therapeutically equivalent drug products" means drug products that contain the same active
239 ingredients and are identical in strength or concentration, dosage form, and route of administration and
240 that are classified as being therapeutically equivalent by the ~~United States~~ U.S. Food and Drug
241 Administration pursuant to the definition of "therapeutically equivalent drug products" set forth in the
242 most recent edition of the Approved Drug Products with Therapeutic Equivalence Evaluations, otherwise

243 known as the "Orange Book."

244 "USP-NF" means the current edition of the United States Pharmacopeia-National Formulary.

245 "Warehouser" means any person, other than a wholesale distributor, engaged in the business of
246 selling or otherwise distributing prescription drugs or devices to any person who is not the ultimate user
247 or consumer. No person shall be subject to any state or local tax by reason of this definition.

248 "Wholesale distribution" means distribution of prescription drugs to persons other than consumers or
249 patients, subject to the exceptions set forth in § 54.1-3401.1.

250 "Wholesale distributor" means any person engaged in wholesale distribution of prescription drugs
251 including, but not limited to, manufacturers; repackers; own-label distributors; private-label distributors;
252 jobbers; brokers; warehouses, including manufacturers' and distributors' warehouses, chain drug
253 warehouses conducting wholesale distributions, and wholesale drug warehouses; independent wholesale
254 drug traders; and retail pharmacies conducting wholesale distributions. No person shall be subject to any
255 state or local tax as a wholesale merchant by reason of this definition.

256 The words "drugs" and "devices" as used in Chapter 33 (§ 54.1-3300 et seq.) and in this chapter
257 shall not include surgical or dental instruments, physical therapy equipment, X-ray apparatus, or glasses
258 or lenses for the eyes.

259 The terms "pharmacist," "pharmacy," and "practice of pharmacy" as used in this chapter shall be
260 defined as provided in Chapter 33 (§ 54.1-3300 et seq.) unless the context requires a different meaning.

261 § 54.1-3408.04. *Dispensing of interchangeable biosimilars permitted.*

262 A. *A pharmacist may dispense a biosimilar that has been licensed by the U.S. Food and Drug
263 Administration as interchangeable with the prescribed product unless (i) the prescriber indicates such
264 substitute is not authorized by specifying on the prescription "brand medically necessary" or (ii) the
265 patient insists on the dispensing of the prescribed biological product. In the case of an oral prescription,
266 the prescriber's oral dispensing instructions regarding dispensing of an interchangeable biosimilar shall
267 be followed. No pharmacist shall dispense a biosimilar in place of a prescribed biological product
268 unless the biosimilar has been licensed as interchangeable with the prescribed biological product by the
269 U.S. Food and Drug Administration for the specific use.*

270 B. *When a pharmacist dispenses an interchangeable biosimilar in the place of a prescribed
271 biological product, the pharmacist or his designee shall inform the patient prior to dispensing the
272 interchangeable biosimilar and shall provide electronic, written, or telephonic notification of the
273 substitution to the prescriber or his staff within five business days of dispensing the interchangeable
274 biosimilar or as set forth in a collaborative agreement as defined in § 54.1-3300. Such notification shall
275 be documented on the record of dispensing. The pharmacist or his designee shall also indicate, unless
276 otherwise directed by the prescriber, on both the record of dispensing and the prescription label, the
277 brand name or, in the case of an interchangeable biosimilar, the product name and the name of the
278 manufacturer or distributor of the interchangeable biosimilar. Whenever a pharmacist substitutes an
279 interchangeable biosimilar pursuant to a prescription written for a brand-name product, the pharmacist
280 or his designee shall label the drug with the name of the interchangeable biosimilar followed by the
281 words "Substituted for" and the name of the biological product for which the prescription was written.
282 Records of substitutions of interchangeable biosimilars shall be maintained by the pharmacist and the
283 prescriber for a period of not less than two years from the date of dispensing.*

284 § 54.1-3457. Prohibited acts.

285 The following acts shall be prohibited:

286 1. The manufacture, sale, ~~or~~ delivery, holding, or offering for sale of any drug, device, or cosmetic
287 that is adulterated or misbranded.

288 2. The adulteration or misbranding of any drug, device, or cosmetic.

289 3. The receipt in commerce of any drug, device, or cosmetic that is adulterated or misbranded, and
290 the delivery or proffered delivery thereof for pay or otherwise.

291 4. The sale, delivery for sale, holding for sale, or offering for sale of any article in violation of
292 § 54.1-3421.

293 5. The dissemination of any false advertisement.

294 6. The refusal to permit entry or inspection, or to permit the taking of a sample, or to permit access
295 to or copying of any record.

296 7. The giving of a false guaranty or undertaking.

297 8. The removal or disposal of a detained article in violation of § 54.1-3459.

298 9. The alteration, mutilation, destruction, obliteration, or removal of the whole or any part of the
299 labeling of, or the doing of any other act with respect to, a drug, device, or cosmetic, if such act is done
300 while such article is held for sale and results in such article being adulterated or misbranded.

301 10. The forging, counterfeiting, simulating, or falsely representing, or without proper authority using
302 of any mark, stamp, tag, label, or other identification device authorized or required by regulations
303 promulgated under the provisions of this chapter or of the federal act.

304 11. The using by any person to his own advantage, or revealing, other than to the Board or its
305 authorized representative or to the courts when relevant in any judicial proceeding under this chapter of
306 any information acquired under authority of this chapter concerning any method or process which as a
307 trade secret is entitled to protection.

308 12. The using, on the labeling of any drug or in any advertisement relating to such drug, of any
309 representation or suggestion that an application with respect to such drug is effective under § 54.1-3421,
310 or that such drug complies with the provisions of such section.

311 13. In the case of a drug distributed or offered for sale in this Commonwealth, the failure of the
312 manufacturer, packer, or distributor thereof to maintain for transmittal, or to transmit, to any practitioner
313 licensed by applicable law to administer such drug who makes written request for information as to such
314 drug, true and correct copies of all printed matter which is required to be included in any package in
315 which that drug is distributed or sold, or such other printed matter as is approved under the federal act.
316 This subdivision shall not be construed to exempt any person from any labeling requirement imposed by
317 or under other provisions of this chapter.

318 14. Placing or causing to be placed upon any drug or device or container, with intent to defraud, the
319 trade name or other identifying mark, or imprint of another or any likeness of any of the foregoing; or
320 selling, dispensing, disposing of, or causing to be sold, dispensed, or disposed of, or concealing or
321 keeping in possession, control, or custody, with intent to sell, dispense, or dispose of, any drug, device,
322 or any container thereof, with knowledge that the trade name or other identifying mark or imprint of
323 another or any likeness of any of the foregoing has been placed thereon in a manner prohibited by this
324 section or making, selling, disposing of, or causing to be made, sold, or disposed of, or keeping in
325 possession, control, or custody, or concealing any punch, die, plate, stone, or other thing designed to
326 print, imprint, or reproduce the trademark, trade name, or other identifying mark, imprint, or device of
327 another or any likeness of any of the foregoing upon any drug or container or labeling thereof so as to
328 render such drug a counterfeit drug.

329 15. The doing of any act ~~which~~ *that* causes a drug to be a counterfeit drug, or the sale or dispensing,
330 or the holding for sale or dispensing, of a counterfeit drug.

331 16. Dispensing or causing to be dispensed a different drug or brand of drug in place of the drug or
332 brand of drug ordered or prescribed without the permission of the person ordering or prescribing, except
333 as provided in § 54.1-3408.03 relating to dispensing of therapeutically equivalent drugs.

334 17. *Dispensing or causing to be dispensed a biosimilar in place of a prescribed biological product*
335 *or brand of biological product, except as provided in § 54.1-3408.04 related to dispensing of*
336 *interchangeable biosimilars.*